Pharma Foods International (2929) · RiskMitigated
Incurrence of Expenses Related to Product Recalls, etc.
First written in FY2018-Q1. 4 of 9 entries say "Mitigated", first in FY2019-Q2. Latest entry: FY2024-Q2.
9entries
8years
0from disclosures
How it moved
Same theme, other companies
Recognition of a provision for product recall-related lossesA theme 15 companies write about · 15 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2024: 3 of 6 companies on the "Worse" side.
8 other companies' latest entry also says "Mitigated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 15 companies compared. The sentences above are computed from all 15.Full recordFilings, disclosures and news, newest first
- FY2024-Q2MitigatedAnnual report
「Product recall-related expenses ¥14 million -」
Product recall-related expenses of ¥14 million were recognized in the same period of the previous year, but none were recognized during the cumulative second quarter. - FY2023MitigatedAnnual report
「Product recall-related expenses - ¥5 million」
Product recall-related expenses of ¥5 million were recognized. Although the amount was down from ¥14 million in the previous fiscal year, the expenses continued to be incurred. - FY2023-Q2MaterialisedAnnual report
「Product recall-related expenses - ¥14 million」
Product recall-related expenses of ¥14 million, which had not been recognized in the same period of the previous year, were recognized again during the cumulative second quarter. - FY2019MitigatedAnnual report
「Product recall-related expenses ¥15.131 million -」
Product recall-related expenses of ¥15.131 million were recognized in the same period of the previous year, but none were recognized for the fiscal year. - FY2019-Q3RestatedAnnual report
「Product recall-related expenses ¥15.131 million -」
The absence of product recall-related expenses recognized for the cumulative third quarter was reconfirmed, compared with ¥15.131 million in the same period of the previous year. - FY2019-Q2MitigatedAnnual report
「Product recall-related expenses ¥15.048 million -」
Product recall-related expenses of ¥15.048 million were recognized in the same period of the previous year, while no amount was reported for the cumulative second quarter. - FY2018-Q3WorsenedAnnual report
「Product recall-related expenses ¥15.131 million」
Product recall-related expenses increased from ¥15.048 million previously to ¥15.131 million. - FY2018-Q2WorsenedAnnual report
「Product recall-related expenses ¥15.048 million」
Product recall-related expenses increased from ¥10.799 million previously to ¥15.048 million, indicating that the scale of recall-related expenses had expanded. - FY2018-Q1First statedAnnual report
「Product recall-related expenses ¥10.799 million」
Product recall-related expenses of ¥10.799 million were recognized as non-operating expenses, disclosing that costs related to the product recall had actually been incurred.